Pembrolizumab

Pembrolizumab
	From PDB entry 5dk3
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	PD-1
Clinical data
Trade names	Keytruda
Other names	MK-3475, lambrolizumab
AHFS/Drugs.com	Monograph
MedlinePlus	a614048
License data	EU EMA: by INN; US DailyMed: Pembrolizumab;
Pregnancy; category	AU: D; not for pregnant women;
Routes of; administration	Intravenous
Drug class	Antineoplastic agents
ATC code	L01FF02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	1374853-91-4;
DrugBank	DB09037;
ChemSpider	none;
UNII	DPT0O3T46P;
KEGG	D10574 ;
ChEMBL	ChEMBL3137343;
ECHA InfoCard	100.234.370
Chemical and physical data
Formula	C6534H10004N1716O2036S46
Molar mass	146648.64 g·mol−1

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is administered by slow intravenous injection.

Common side effects include fatigue, musculoskeletal pain, decreased appetite, itchy skin (pruritus), diarrhea, nausea, rash, fever (pyrexia), cough, difficulty breathing (dyspnea), constipation, pain, and abdominal pain. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells, allowing the immune system to destroy them. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes.

Pembrolizumab was approved for medical use in the United States in 2014. It is on the World Health Organization's List of Essential Medicines.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.